Page 2 of Biocon

stocks to watch, stock in news, stocks in news

Stocks To Watch: From TCS to RVNL- Here’s a list of 10 stocks in news today

Explore today’s key stocks: TCS, Bajaj, Biocon, and more are making headlines with big deals and investments. Stay informed now!

March 7, 2025 06:40 IST

Biocon Biologics partners with Civica to expand Insulin Aspart access in United States

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical trials.

March 6, 2025 18:12 IST

Stocks To Watch: From Biocon to Ola Electric- Here’s a list of 10 stocks in news today

Track key stocks like Biocon, Jio Financial, and Adani Wilmar making headlines today. Discover market impacts and stay informed!

March 5, 2025 06:46 IST

Jefferies bets big on these 3 pharma stocks- Find out why

Jefferies backs Lupin, Zydus, and Biocon amid shifting US pharma market shares. Discover why these stocks are set to shine.

March 4, 2025 14:31 IST

Biocon Biologics launches biosimilar to treat Crohn’s disease in United States

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

February 24, 2025 17:31 IST

Biocon shares up 4% despite sharp fall in profit, find out why?

Biocon share price today, January 31: Biocon shares rise 4% amid Q3 FY25 profit drop; explore reasons behind investor optimism.

January 31, 2025 14:30 IST

Biocon Q1 Result, Biocon Q1 Results 2024, Biocon Q1 Results 2024, Biocon Q1 Earning, Biocon Q1 Profit, Biocon Q1 Net Profit, Biocon Q1 FY25 Results 2024

Biocon urges government to exempt cancer, rare-disease drugs from tax in Budget 2025

To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties for high-tech…

January 20, 2025 16:52 IST

USFDA gives nod to Biocon Biologics’ biosimilar to treat Crohn’s disease

The biosimilar is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis.

December 1, 2024 19:49 IST

USFDA grants ‘VAI’ tag to Biocon’s Bengaluru facility

Following the development, the company’s share price rose up to 5.69 per cent to hit an intraday high of Rs…

November 11, 2024 14:27 IST

Need to strengthen national policies to increase access and adoption of biosimilars, reveals new report

In LMICs, where healthcare budgets are often stretched and large segments of the population remain underserved, the introduction of biosimilars…

October 8, 2024 15:40 IST

Biocon Biologics refinances $1.1 Billion long term debt

Additionally, Biocon Biologics has entered into a commitment agreement for a new syndicated debt facility, the company announced.

October 3, 2024 15:49 IST

Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public

Bicara Therapeutics, a clinical-stage biopharmaceutical company, focuses on bringing transformative bifunctional therapies for patients with solid tumors.

September 27, 2024 14:32 IST

Biocon Q1 Results: Net profit jumps 14% to Rs 660 crore, revenue up 30% to Rs 4,567 crore

Biocon Q1 Net Profit: Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited revealed that having successfully integrated the acquired…

August 9, 2024 12:21 IST

Biocon Q1 Results 2024: Date, Earnings Call Time, and Where to Watch?

Biocon Q1 FY25 Results 2024: The results for Biocon’s Q1 results for FY24 will also be published on both the…

August 7, 2024 18:35 IST

Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab at its new facility in Bengaluru

The facility has previously been approved to manufacture biosimilar Trastuzumab in September 2022.

June 24, 2024 12:28 IST

Biocon appoints Mukesh Kamath as interim CFO

Biocon appointed Mukesh Kamath, Head – Business Finance R&D, as the interim chief financial officer and key managerial personnel of…

June 11, 2024 16:39 IST

Biocon Biologics, Biocon, b2b, b2c, Shreehas Tambe, industry

Aim is to be among top three biosimilars players globally: Biocon Biologics CEO Shreehas Tambe

‘Biocon Biologics has successfully transitioned from a B2B to B2C company following the integration of the acquired business.’

May 27, 2024 02:15 IST

Biocon signs exclusive licensing deal for comercialisation of obesity drug in South Korea

The total addressable market opportunity of Liraglutide in Korea is approximately US $47 million as per the IQVIA MAT Q4…

May 24, 2024 09:17 IST

Related News

Aadhaar rule change 2025: New UIDAI update fees, PAN-Aadhaar link and KYC rules explained

Aadhaar rule change 2025: New UIDAI update fees, PAN-Aadhaar linking and KYC rules explained

‘Worship of false gods’: MAGA spreads hate on Diwali as Trump lights diyas at White House

Stepping inside Parineeti Chopra and Raghav Chadha’s dreamy homes, where luxury and warmth reside together

WinTrack highlighted a case of an entrepreneur allegedly harassed by customs at Indira Gandhi International Airport in Delhi, stressing that “genuine entrepreneurs face harassment frequently”.

‘Reccuring problem at Indian airports’: Wintrack highlights case of entrepreneur harassed by customs at Delhi Airport

Business tycoon Anand Mahindra shared a serene glimpse of Palakkad, Kerala, calling it “the perfect escape” from modern life’s chaos.

‘Not a tourist destination, nor…’: Anand Mahindra calls Kerala’s Palakkad village ‘the perfect escape’ from modern life

‘NIM will improve by 10–15 bps by Q4,’ says Ashok Chandra, MD & CEO, Punjab National Bank

Business15 min ago

PNB’s MD & CEO, Ashok Chandra, expects a 10-15 bps NIM improvement by Q4, driven by green shoots in private capex and margin recovery. The bank anticipates minimal impact from ECL norms and sees GST cuts driving retail and MSME lending. PNB’s recoveries have outpaced slippages for 6-7 quarters, leading to a strong recovery of Rs 3,900 crore. The bank’s subsidiaries are also performing well

View all shorts